Furthermore, the same methylation served as a critical step for PD-1/PD-L1 interaction and as a negative predictive biomarker for anti-PD-1 treatment in patients suffering from NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.